Is Trump’s MFN pricing order more bark than bite?

In this episode of The Top Line, Ayla Ellison introduces Fierce Pharma's Eric Sagonowski and Fraiser Kansteiner, who delve into President Trump's letters to 17 major pharma companies demanding the implementation of Most Favored Nation (MFN) drug pricing in the U.S. The discussion covers the potential impact of MFN pricing, the reactions from drug companies and industry groups like PhRMA, and the historical context of drug pricing reforms, including the Inflation Reduction Act. Additionally, the episode explores the role of tariffs and biopharma companies' investment plans in the U.S. in relation to drug pricing negotiations, providing an analysis of the political theater and behind-the-scenes maneuvering in the pharmaceutical industry.